Denmark · Delayed Price · Currency is DKK Novozymes Statistics
Total Valuation
Novozymes has a market cap or net worth of DKK 163.35 billion. The enterprise value is 183.74 billion.
| Market Cap | 163.35B |
| Enterprise Value | 183.74B |
Important Dates
The last earnings date was Wednesday, February 25, 2026.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | Mar 24, 2026 |
Share Statistics
Novozymes has 465.91 million shares outstanding. The number of shares has increased by 68.00% in one year.
| Current Share Class | 412.17M |
| Shares Outstanding | 465.91M |
| Shares Change (YoY) | +68.00% |
| Shares Change (QoQ) | -0.32% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 29.42% |
| Float | 346.63M |
Valuation Ratios
The trailing PE ratio is 37.56 and the forward PE ratio is 22.21. Novozymes's PEG ratio is 5.96.
| PE Ratio | 37.56 |
| Forward PE | 22.21 |
| PS Ratio | 5.26 |
| PB Ratio | 2.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 26.95 |
| P/OCF Ratio | 17.91 |
| PEG Ratio | 5.96 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.08, with an EV/FCF ratio of 30.31.
| EV / Earnings | 42.16 |
| EV / Sales | 5.92 |
| EV / EBITDA | 16.08 |
| EV / EBIT | 25.76 |
| EV / FCF | 30.31 |
Financial Position
The company has a current ratio of 0.72, with a Debt / Equity ratio of 0.28.
| Current Ratio | 0.72 |
| Quick Ratio | 0.43 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.96 |
| Debt / FCF | 3.70 |
| Interest Coverage | 14.08 |
Financial Efficiency
Return on equity (ROE) is 5.30% and return on invested capital (ROIC) is 5.56%.
| Return on Equity (ROE) | 5.30% |
| Return on Assets (ROA) | 3.81% |
| Return on Invested Capital (ROIC) | 5.56% |
| Return on Capital Employed (ROCE) | 7.07% |
| Weighted Average Cost of Capital (WACC) | 7.58% |
| Revenue Per Employee | 2.80M |
| Profits Per Employee | 392,736 |
| Employee Count | 11,263 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 2.48 |
Taxes
In the past 12 months, Novozymes has paid 1.19 billion in taxes.
| Income Tax | 1.19B |
| Effective Tax Rate | 21.50% |
Stock Price Statistics
The stock price has decreased by -15.03% in the last 52 weeks. The beta is 0.75, so Novozymes's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -15.03% |
| 50-Day Moving Average | 382.96 |
| 200-Day Moving Average | 408.50 |
| Relative Strength Index (RSI) | 38.18 |
| Average Volume (20 Days) | 820,580 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novozymes had revenue of DKK 31.05 billion and earned 4.36 billion in profits. Earnings per share was 9.34.
| Revenue | 31.05B |
| Gross Profit | 17.22B |
| Operating Income | 7.18B |
| Pretax Income | 5.55B |
| Net Income | 4.36B |
| EBITDA | 11.48B |
| EBIT | 7.18B |
| Earnings Per Share (EPS) | 9.34 |
Balance Sheet
The company has 2.06 billion in cash and 22.45 billion in debt, with a net cash position of -20.39 billion or -43.76 per share.
| Cash & Cash Equivalents | 2.06B |
| Total Debt | 22.45B |
| Net Cash | -20.39B |
| Net Cash Per Share | -43.76 |
| Equity (Book Value) | 81.07B |
| Book Value Per Share | 174.01 |
| Working Capital | -5.66B |
Cash Flow
In the last 12 months, operating cash flow was 9.12 billion and capital expenditures -3.06 billion, giving a free cash flow of 6.06 billion.
| Operating Cash Flow | 9.12B |
| Capital Expenditures | -3.06B |
| Depreciation & Amortization | 4.30B |
| Net Borrowing | 9.06B |
| Free Cash Flow | 6.06B |
| FCF Per Share | 13.01 |
Margins
Gross margin is 55.45%, with operating and profit margins of 23.13% and 14.04%.
| Gross Margin | 55.45% |
| Operating Margin | 23.13% |
| Pretax Margin | 17.88% |
| Profit Margin | 14.04% |
| EBITDA Margin | 36.96% |
| EBIT Margin | 23.13% |
| FCF Margin | 19.52% |
Dividends & Yields
This stock pays an annual dividend of 6.50, which amounts to a dividend yield of 1.85%.
| Dividend Per Share | 6.50 |
| Dividend Yield | 1.85% |
| Dividend Growth (YoY) | 61.25% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 69.00% |
| Buyback Yield | -68.00% |
| Shareholder Yield | -66.15% |
| Earnings Yield | 2.67% |
| FCF Yield | 3.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 28, 2011. It was a forward split with a ratio of 5.
| Last Split Date | Nov 28, 2011 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Novozymes has an Altman Z-Score of 4.19 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.19 |
| Piotroski F-Score | 6 |